These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37310474)

  • 1. Osimertinib is a dual inhibitor of hepatocellular carcinoma and angiogenesis in an EGFR-independent manner, and synergizes with venetoclax.
    Huang Q; He S; Zhan D
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10727-10735. PubMed ID: 37310474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
    Liu Y; Sun L; Su X; Guo S
    Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis.
    Zhong L; Yang S; Jia Y; Lei K
    J Cell Biochem; 2018 Dec; 119(12):9742-9751. PubMed ID: 30145799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
    Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
    Tan J; Ye J; Song M; Zhou M; Hu Y
    J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29112301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.
    Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G
    Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway.
    Chen C; Cheng CD; Wu H; Wang ZW; Wang L; Jiang ZR; Wang AL; Hu C; Dong YF; Niu WX; Qi S; Qi ZP; Liu J; Wang WC; Niu CS; Liu QS
    Acta Pharmacol Sin; 2021 Jan; 42(1):108-114. PubMed ID: 32398685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
    Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
    Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
    Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
    Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribavirin inhibits the growth and ascites formation of hepatocellular carcinoma through downregulation of type I CARM1 and type II PRMT5.
    Tian Y; Yang W; Yang R; Zhang Q; Hao L; Bian E; Yang Y; Huang X; Wu Y; Zhang B
    Toxicol Appl Pharmacol; 2022 Jan; 435():115829. PubMed ID: 34919946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA TSLNC8 synergizes with EGFR inhibitor osimertinib to inhibit lung cancer tumorigenesis by blocking the EGFR-STAT3 pathway.
    Zhou SZ; Li H; Wang ZW; Wang MH; Li N; Wang YF
    Cell Cycle; 2020 Nov; 19(21):2776-2792. PubMed ID: 33064977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
    Shi P; Oh YT; Deng L; Zhang G; Qian G; Zhang S; Ren H; Wu G; Legendre B; Anderson E; Ramalingam SS; Owonikoko TK; Chen M; Sun SY
    Clin Cancer Res; 2017 Nov; 23(21):6567-6579. PubMed ID: 28765329
    [No Abstract]   [Full Text] [Related]  

  • 17. Long non-coding RNA TPTEP1 inhibits hepatocellular carcinoma progression by suppressing STAT3 phosphorylation.
    Ding H; Liu J; Zou R; Cheng P; Su Y
    J Exp Clin Cancer Res; 2019 May; 38(1):189. PubMed ID: 31072375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1.
    Wirth T; Kühnel F; Fleischmann-Mundt B; Woller N; Djojosubroto M; Rudolph KL; Manns M; Zender L; Kubicka S
    Cancer Res; 2005 Aug; 65(16):7393-402. PubMed ID: 16103092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
    Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
    Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.